HomeTrading IdeasFed Aftermath: Core Inflation...

Fed Aftermath: Core Inflation Is Back to 2%—So Why the Hawkish Tone?

Let’s start this macro piece with a little game.

Below you find two tables representing 3 consecutive prints of in the US including its subcomponents: core goods and core services (with a separate mention for ‘’supercore’’ CPI).

Without using Bloomberg or Google (NASDAQ:), are you able to tell which 3-month core CPI streak belongs to the pre-pandemic period and which one to today?

I wasn’t, and some of the hedge fund PMs I asked the same question ended up making a mistake.

In both cases, core CPI MoM prints were averaging 0.15-0.20 which is broadly in line with the annual 2% target and the subcomponents painted a picture of 0% goods inflation with core and super-core responsible for the quite muted inflationary pressures.

The answer: section 2 covers the Jun-Aug 2019 period, and section 1 shows Core CPI for Mar-May 2025.

I think we should take some time to reflect on this.

In early 2019, Powell pivoted dovish with a clear speech highlighting the tightening cycle was over and the was all about accommodating financial conditions.

averaged 0.2% MoM in summer (higher than today), was 3.7% (lower than today, and stable), and the Fed moved on to cut rates from 2.25% to 1.50% in Q3 2019.

Fast forward to today: the last 3 core inflation prints averaged 0.14% MoM with weaker services inflation, unemployment rate is steadily climbing up at 4.24%, and Fed Funds sit 200 bps above summer 2019.

The Fed might soon capitulate dovish.

Also, amidst this tariff noise it’s helpful to take a step back and remember core goods only represent ~20% of the core CPI basket.

The real action lies in services and housing (dis)inflation.

The guys at WisdomTree developed a real-time core inflation metric that uses actual housing inflation rather than the lagging shelter CPI metric:Trailing 12M Core CPI

Core CPI using real-time shelter inflation (blue) has been around 2% for 18 months already, but the lagging nature of shelter CPI (grey) pushed official core CPI higher limiting the ability for the Fed to cut.

The lagged disinflation in housing seems set to continue, which means the official core CPI measure might keep declining based on official shelter inflation dropping (it’s 35-40% of the core CPI basket: it matters).

Notice how using real-time shelter inflation works both ways.

The red circle highlights the mid-2021 period when the housing market was ultra hot but shelter inflation didn’t yet show up in the official core CPI – which tricked the Fed into mistakenly delaying the hiking cycle.

The opposite has happened in 2024, but the last 3 core CPI prints are now decisively dovish.

It’s time to follow the Fed very closely to grasp when the dovish turn might come.

The title of this piece is ‘’null komma null’’, a German expression which means 0.0 and we can say the excess inflation today compared to pre-pandemic periods is actually null komma null.

But there is another ‘’null komma null’’ which is crucial for markets and asset allocation.

A close friend, mentor and hedge fund PM recently had a chat with a German pension fund manager and asked him how much additional USD hedging they have done given the correlation break between and risk assets.

‘’Null komma null’’. Nothing, no additional hedging has been done.

Basically, pension funds and insurance companies remain very long (and hurting) the :

FX Exposure

The reason is very simple: FX hedging costs are still high, and pension funds/insurance companies have return targets to meet.

Picture this: the standard return requirement for a pension fund is 6.5/7.0%, and if you are in Switzerland or Japan hedging your USD/CHF and exposure for the next 12 months costs 3.5-4.0%.

That’s quite a hefty negative carry to pay, and this deters pension funds managers from hedging.

But.

In a scenario where:

  1. The Fed turns dovish and starts delivering cuts

  2. USD hedging costs start to drop

  3. The USD depreciates further, reminding foreign pension funds of their losing long USD position

We could see a fast acceleration in USD hedging demand from foreign whales around the world.

Such hedging activity would compound USD weakness very rapidly.

If such an outcome unravels, the market implications are pretty straightforward.

Short the denominator, long the numerator.

The US Dollar remains the denominator of most financial assets out there, and the combo of a dovish Fed turn + Trump policies + hedging activity would definitely ‘’weaken the denominator’’.

When it comes to the ‘’numerator’’ (i.e. what asset you go long vs the USD), my view is:

  • FX: prefer currencies potentially involved in hedging flows (EUR, CHF, JPY, , etc)

  • Equities: prefer sector/countries with high pricing power (tech, large cap) or commodity exporters

  • Commodities: long metals (, etc)

This article was originally published on The Macro Compass. Come join this vibrant community of macro investors, asset allocators and hedge funds – check out which subscription tier suits you the most using this link.

Most Popular

More from Author

Oil Price Retreats but Bullish Technicals Suggest Upside Ahead

The NA session kicks off quietly, with subdued volumes as American...

Stocks Week Ahead: Can Small-Business Optimism, Inflation Clues Keep Bulls Alive?

There’s not much on this week’s economic calendar. The only big...

June Payrolls Jump, but Other Growth Indicators Paint a Sluggish Picture

June beats consensus on the back of education and health...

Fed Gets Breathing Room as Labor Market Holds Firm

The monthly jobs report hit today (unusually, on a Thursday, due...

Read Now

Oil Price Retreats but Bullish Technicals Suggest Upside Ahead

The NA session kicks off quietly, with subdued volumes as American traders take the day off, giving markets a breather after the upside surprise in the last week and fresh diplomatic updates from the US. From a price action perspective, has been consolidating in a narrow...

Stocks Week Ahead: Can Small-Business Optimism, Inflation Clues Keep Bulls Alive?

There’s not much on this week’s economic calendar. The only big event was supposed to occur on Wednesday, July 9. That would have been 90 days after President Donald Trump postponed his April 2 reciprocal tariffs on America’s trading partners on April 9 for 90 days. Today,...

June Payrolls Jump, but Other Growth Indicators Paint a Sluggish Picture

June beats consensus on the back of education and health services employment, while private NFP surprises downside. With S&P Global monthly flat over the last six months through May, many key indicators followed by the NBER  Business Cycle Dating Committee (BCDC) are flat or falling...

Fed Gets Breathing Room as Labor Market Holds Firm

The monthly jobs report hit today (unusually, on a Thursday, due to the real and perfectly sensible holiday tomorrow blocking the typical Friday release) and the reaction was immediate. All the equity futures remain strong, but paradoxically, it can sometimes be a spike to the upside that...

How California’s Housing Reforms Could Reshape US Cities Over the Next Decade

Things are moving fast these days. Texans for Reasonable Solutions, among others, has helped push through a number of housing reforms in Texas. Maine has passed a couple of bills that should allow more step-change urban development, as I put it in the “Market Segmentation” post. And California has suddenly...

Week Ahead – RBA, RBNZ Decisions and Fed Minutes Eyed as Trade Deals Awaited

July 9 tariff deadline looms as trade deals remain elusive Fed minutes to be watched after positive jobs report RBA expected to cut but RBNZ to likely stay on hold OPEC+ to probably raise output again UK GDP, Canadian employment and Chinese CPI data also on tap The Race to the Finish...

The Fiscal Treadmill Is Speeding Up and Washington Keeps Jogging

As of 1980, the rolling 10-year and 20-year real GDP growth rates stood at 3.2% per annum and 3.5% per annum, respectively. Owing to a slight boost from the good parts of Reaganomics—sweeping deregulation, tax rate cuts, and sound money, which were partially offset by the long-term ills...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera's Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy SolutionsDistinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera's Scientific Advisory Board.Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.In collaboration...

Risk Assets Extend Gains but Low Volumes Could Skew Monday Open

Yesterday’s market action was driven by consecutive upside surprises in US (147K vs 110K exp) and data (50.8 vs 50.5 exp), fueling another wave of positive sentiment and pushing US equities into yet another frenzied rally. The reaction to the data was progressive but consistent, taking...

Risk-On Sentiment Fades as Tariffs Return to the Spotlight

Dollar surrenders gains posted after robust labour market report Trump celebrates US budget bill approval; scheduled to sign it today Most Fed members feel more comfortable as July rate cut is priced out Oil steadies near $66, gold rally retains momentum Thursday Proved to Be Rather EventfulWhile the US is celebrating...

Oil Prices Set to End the Week With a Modest Gain

prices were on course for a modest weekly gain today, buffeted by both headwinds and tailwinds, including OPEC+ policy, U.S. job numbers, and anticipation of President Trump’s next move on tariffs. At the time of writing, was trading at $68.58 per barrel, with West Texas Intermediate...

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer’s Trial Data – Cognition Therapeutics (NASDAQ:CGTX), InMed Pharmaceuticals (NASDAQ:INM)

Cognition Therapeutics Inc CGTX rose 12.10% to $0.45 during after hours on Thursday, following a surge of 20.82% gain during regular hours. What Happened: The hike in Cognition Therapeutics’ stock price is attributed to the promising results from its Alzheimer’s drug, Zervimesine. The drug achieved a 95% efficacy...